Abstracts tagged "B-Lymphocyte"

Abstract Number: 0982 • ACR Convergence 2025
Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
cristiana Sieiro¹, Juan García Herrero², Jose Ordas Martínez³, Carolina Álvarez Castro³, Alejandra López Robles³, Ronald Colindres³, Ana María Sahagún⁴ and Jose María Ruiz de Morales³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²complejo asistencial universitario de leon, León, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴University of Leon, León, Spain
Background/Purpose: Herpes zoster (HZ) is a common infection, particularly in older adults and women, and can lead to complications like neuropathic pain. The risk is…
Abstract Number: 1838 • ACR Convergence 2025
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: L16 • ACR Convergence 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Megan Clowse¹, David Isenberg², Joan Merrill³, Thomas Dörner⁴, Michelle Petri⁵, Edward Vital⁶, Eric Morand⁷, Teri Jimenez⁸, Stephen Brookes⁹, Janine Gaiha-Rohrbach¹⁰, Christophe Martin¹¹, Annette Nelde¹² and Christian Stach¹³, ¹Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁸UCB, Raleigh, NC, ⁹Biogen, Maidenhead, United Kingdom, ¹⁰Biogen, Cambridge, MA, ¹¹UCB, Slough, United Kingdom, ¹²Biogen, Baar, Switzerland, ¹³UCB, Monheim am Rhein, Germany
Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
Abstract Number: 0012 • ACR Convergence 2024
Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis
Ken Yasaka, Ruoqiao Wang, Nida Pellett, Daria Krenitsky, Juilee Thakar and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The gut is a key mucosal tissue that can impact the immune system and contribute to systemic inflammation in the setting of increased intestinal…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1804 • ACR Convergence 2024
Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development
Aleksandra Bylinska¹, Miles Smith¹, Rufei Lu¹, Benjamin Jones², Carla Guthridge¹, Matthew Caleb Marlin¹, Christian Wright³, Susan Macwana³, Wade DeJager³, Marci Beel³, Christopher Lessard¹, Cristina Arriens¹, Joan Merrill⁴, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Ana Merino Vico¹, Yosta Vegting¹, Aldo Jongejan¹, Jan Piet van Hamburg¹, Perry moerland¹, Sander Tas² and Marc Hilhorst¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
Abstract Number: 0911 • ACR Convergence 2024
Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants
David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
Abstract Number: 1807 • ACR Convergence 2024
Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus
Takehiro Hirayama¹, Hyota Takamatsu² and Atsushi Kumanogoh³, ¹Osaka university, ibaraki city, Japan, ²National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, ³Osaka University, Osaka, Japan
Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
Abstract Number: 0016 • ACR Convergence 2024
Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology
Lichchavi Rajasinghe¹, Govinda Rocky Thomas,², Jee Ho Lee¹, Gary Sims¹ and Tatiana Ort¹, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²AstraZeneca Pharmaceuticals, Gaithersburg, MD
Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
Abstract Number: 1842 • ACR Convergence 2024
Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
John Goulding¹, John Reiser², Alison O'Connor¹, Bryan Hancock¹, Jonatan Tuncel¹, Brian Groff¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Allan Williams¹, Dan Lu¹, Bi-Huei Yang¹, Eigen Peralta¹, Alma Gutierrez¹, Miguel Meza¹, Betsy Rezner¹, Amanda Sims¹, Alec Witty¹, Yijia Pan¹, Mark Jelcic¹, Shohreh Sikaroodi¹, Matthew Denholtz¹, Tom Lee¹, Anil Bagri¹, Lilly Wong¹, Jode Goodridge¹ and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Fate Therapeutics Inc, San Diego, CA
Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
Abstract Number: 0017 • ACR Convergence 2024
Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction
Sang Jin Lee¹, Nan Young Lee², Eun Joo Lee³, Ji Ae Jang³, Gun Woo Kim³ and Eon Jeong Nam², ¹Kyungpook National University Hospital, Daegu, Republic of Korea, ²Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, ³Daegu Fatima Hospital, Daegu, Republic of Korea
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a prototypical autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, where complex interactions between innate and adaptive…
Abstract Number: 1381 • ACR Convergence 2024
Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Cécile Bergua¹, Marine Besnard¹, Ghenima Ahmil², Laure-Helene Ouisse², Nadège Vimond¹, Apolline Salama², Bérangère Evrard², Elise Brisebard³, Alexis Collette¹, Fréderic Blanchard⁴, Thibault Larcher³, Ronald Van Brempt¹, Benoit Le Goff⁵, Ignacio Anegon² and Carole Guillonneau¹, ¹AbolerIS Pharma, Nantes, France, Nantes, France, ²Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, ³APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, ⁴INSERM UMR1229, Nantes, France, Nantes, France, ⁵CHU Nantes, France, Nantes, France
Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].